Lawal, Ismaheel O

Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study

Sathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 210

mCRPC Patients Receiving 225 Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis

Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Mdlophane, A., Maes, A., Mokoala, K., et al. (2022) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research

Cited by 81

Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT

Lawal, I., Vorster, M., Boshomane, T., Ololade, K., Ebenhan, T., & Sathekge, M. (2015) · Clinical Nuclear Medicine

Prostate Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications

Cited by 20